Benitec Biopharma (BNTC) Cash from Operations (2019 - 2025)
Benitec Biopharma has reported Cash from Operations over the past 7 years, most recently at 3749000.0 for Q4 2025.
- Quarterly results put Cash from Operations at 3749000.0 for Q4 2025, up 51.33% from a year ago — trailing twelve months through Dec 2025 was 18399000.0 (up 15.57% YoY), and the annual figure for FY2025 was 23588000.0, down 21.57%.
- Cash from Operations reached 3749000.0 in Q4 2025 per BNTC's latest filing, down from 3351000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 1989000.0 in Q1 2021 and bottomed at 8213000.0 in Q2 2025.
- Median Cash from Operations over the past 5 years was 4197500.0 (2021), compared with a mean of 4555850.0.
- The largest annual shift saw Cash from Operations crashed 158.65% in 2021 before it soared 51.33% in 2025.
- Over 5 years, Cash from Operations stood at 3322000.0 in 2021, then crashed by 76.25% to 5855000.0 in 2022, then rose by 9.48% to 5300000.0 in 2023, then tumbled by 45.34% to 7703000.0 in 2024, then skyrocketed by 51.33% to 3749000.0 in 2025.
- Business Quant data shows Cash from Operations for BNTC at 3749000.0 in Q4 2025, 3351000.0 in Q3 2025, and 8213000.0 in Q2 2025.